Hugel
Hugel is a South Korean medical-aesthetics company that develops and manufactures botulinum toxin type A products, including Botulax and Letybo. Botulax anchors its Korean product history, while Letybo is used in the United States and several international markets. Hugel’s official brand information 🔗 distinguishes these market identities; the U.S. prescribing information 🔗 identifies Hugel as Letybo’s manufacturer in Chuncheon, Korea.
Botulax and Letybo are related Hugel toxin names rather than a simple global synonym with one universal label. Product names, approved indications, vial strengths, distribution partners, and prescribing information differ by country.
Quick Answers
Section titled “Quick Answers”| Common question | Short answer |
|---|---|
| Who makes Letybo? | Hugel manufactures Letybo in Korea. In the United States, the product is letibotulinumtoxinA-wlbg, approved for temporary improvement of moderate to severe glabellar lines in adults. |
| What is the relationship between Botulax and Letybo? | Botulax is Hugel’s Korean and export-associated toxin name; Letybo is the internationally visible name used for the U.S. product and other markets. The names should not be read as one universal label. |
| Is Botulax FDA approved in the United States? | The current U.S. label is Letybo, not Botulax. U.S. interpretation should start with the Letybo prescribing information rather than Korean Botulax approval history. |
| Are regional Hugel toxin names interchangeable? | No. Botulax, Letybo, Aestox, Hugeltox, and other regional names can point to Hugel-related market identities, but approval status, indications, units, and product information remain local. |
| Who leads Hugel? | Carrie Strom is President and Global CEO; Daniel Chang is Korea CEO. Hugel identifies both roles in its November 4, 2026 results announcement. |
| Who sells Letybo in the United States? | Letybo launched through BENEV in March 2025. Hugel added its own sales team in 2026 and reported a move from a distributor partnership to a contract sales organization (CSO) model in November 2026. |
The leadership and sales-model updates come from Hugel’s Q1–Q3 2026 announcement 🔗. The U.S. commercial sequence is detailed below; product approval and the current approved use are separate from sales arrangements.
Reference card
Section titled “Reference card”| Field | Reference point |
|---|---|
| Company | Hugel Inc. |
| Base | South Korea |
| Website | hugel-inc.com 🔗 |
| Listing status | KOSDAQ-listed; company code 145020 (DART company information 🔗) |
| Manufacturing footprint | Hugel lists its head office and Geodu Factory in Chuncheon and a Seoul office in Gangnam. |
| Core toxin relationship | Developer and manufacturer of botulinum toxin type A products |
| Main toxin names | Botulax, Letybo |
Related People
Section titled “Related People”| Person | Why the relationship matters |
|---|---|
| Daniel Chang | Korea CEO, distinguishing leadership of the Korean business from the global CEO role. |
| Carrie Strom | Hugel’s President and Global Chief Executive Officer, connecting Hugel’s global expansion with earlier Allergan Aesthetics leadership experience around Botox Cosmetic and other aesthetic products. |
Strom began the newly established global CEO role on October 13, 2025. Hugel’s appointment announcement 🔗 placed the executive leadership team, including the head of Hugel Korea, under that role.
Selected history
Section titled “Selected history”-
2001: company founding Hugel dates its foundation to 2001 and describes a portfolio spanning toxin, fillers, skin boosters, sutures, and cosmetics. (Hugel company overview 🔗)
-
2010-2019: Botulax indication expansion in Korea Hugel lists HG 101 (Botulax) milestones for eyelid spasm in 2010, glabellar lines in 2012, post-stroke upper-limb muscle stiffness and cerebral-palsy equinus foot in 2016, and eye wrinkles in 2019. (Hugel R&D status 🔗)
-
2022: Australian Letybo registration Australia’s TGA approved Letybo on November 23, 2022 and registered it on November 28 for temporary improvement of moderate to severe glabellar frown lines in adults. (TGA Letybo decision 🔗)
-
2024: U.S. FDA approval for Letybo FDA records list Letybo, letibotulinumtoxinA-wlbg, as approved on February 29, 2024 for temporary improvement in the appearance of moderate to severe glabellar lines in adults. (FDA Letybo approval snapshot 🔗)
-
2025–2026: U.S. launch and commercial expansion Letybo launched in the United States in March 2025 through BENEV. Hugel announced a dedicated U.S. sales force in July 2026, separating the commercial rollout from the earlier FDA approval. (Hugel Aesthetics U.S. expansion announcement 🔗)
Product portfolio
Section titled “Product portfolio”Hugel’s botulinum toxin business centers on a type A product family presented through different names across markets. Shared company origin does not establish identical local labels or a common dose scale.
| Product name | Main context | Presentation / label context | Market and approval boundary |
|---|---|---|---|
| Botulax | Hugel’s Korean and export-associated botulinum toxin type A name. | Hugel R&D materials identify HG 101 as Botulax and list Korean indication milestones from 2010 onward. | Korean approval history does not automatically transfer to other countries or to the Letybo label used elsewhere. |
| Letybo | International market name used for Hugel’s letibotulinumtoxinA product, including the U.S. product. | U.S. labeling describes Letybo as letibotulinumtoxinA-wlbg for injection, supplied as lyophilized powder for intramuscular use. | U.S. approval is for glabellar lines in adults; units and indications remain product- and market-specific. |
Botulax
Section titled “Botulax”
Botulax is the Hugel toxin name most closely tied to the company’s Korean approval and manufacturing history. The company’s R&D record identifies it as HG 101; its Botulax brand information 🔗 includes aesthetic and therapeutic indications with product- and country-specific authorization limits.
That history makes Botulax important to the Korean botulinum toxin ecosystem, but it should not be used as a shortcut for global approval status. A product that is approved or marketed in Korea can have different labeling, indication language, vial presentations, and commercial names elsewhere.
Letybo
Section titled “Letybo”
Letybo is Hugel’s internationally visible type A toxin name. In the United States, Letybo is letibotulinumtoxinA-wlbg, indicated for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. The U.S. label 🔗 lists 50-unit and 100-unit single-dose vials of freeze-dried powder and states that Letybo is not approved for spasticity or conditions other than glabellar lines.
The U.S. label is also a useful unit-safety anchor. It states that Letybo potency units are specific to the product’s preparation and assay and cannot be compared with or converted into units of another botulinum toxin product. That warning matters because Letybo may appear in the same comparison conversations as Botox, Dysport, Xeomin, Daxxify, or Jeuveau, but shared type A biology does not create a shared dose scale.
Hugel’s regional brand information 🔗 lists Aestox in Thailand, Hugeltox in the Philippines, and Magnion, Reage, and Juvenlife in Central and South America. These are market identifiers; they do not establish identical labels, indications, or availability across countries.
U.S. commercialization and international expansion
Section titled “U.S. commercialization and international expansion”Hugel manufactures Letybo, while its sales arrangements determine how the product reaches practices. U.S. commercial milestones have followed a different timetable from FDA approval:
| Milestone | Commercial arrangement |
|---|---|
| March 2025 launch | Letybo entered the U.S. market through a strategic partnership with BENEV. |
| July 21, 2026 announcement | Hugel described a hybrid approach: its own sales organization would focus on selected strategic accounts while BENEV continued serving other accounts. |
| November 4, 2026 announcement | Hugel reported converting the distributor partnership to a CSO model, under which a partner provides contracted sales services. |
The July U.S. expansion announcement 🔗 describes the hybrid arrangement. The later Q1–Q3 results announcement 🔗 reports the CSO transition and a short-term impact on results. This changes the commercial relationship; it does not establish a new product approval or expanded indication.
Outside the United States, Hugel announced Letybo’s Indian launch on July 22, 2026, following the July 19–21 Global Aesthetics Summit in Goa, with Aakaar Medical as its local distributor. The announcement establishes a launch and commercial partner, rather than the scope of an Indian prescribing label. (Hugel India launch announcement 🔗)
Manufacturing and office sites
Section titled “Manufacturing and office sites”Hugel’s listed Korean sites connect the company to both manufacturing and business coordination. Company statements about cGMP-based systems, KGMP certification, or adherence to international GMP standards are manufacturing-quality context, not automatic evidence of every regulator’s product approval in every market.
Head office and Geodu Factory: Chuncheon
Section titled “Head office and Geodu Factory: Chuncheon”Hugel describes the Geodu site in Chuncheon as a facility for both drug substance and finished drug product. It reports Korean KGMP certification in 2016 and operation based on cGMP standards. (Hugel quality and manufacturing information 🔗)
Location: 23, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gangwon-do, Republic of Korea 🔗.
Seoul Office: Gangnam
Section titled “Seoul Office: Gangnam”Hugel’s official office listings 🔗 identify a Seoul office in Gangnam, separate from the Chuncheon head office and manufacturing site.
Location: 17, Samseong-ro 133-gil, Gangnam-gu, Seoul, Republic of Korea 🔗.
Market role
Section titled “Market role”Hugel is one of the clearest examples of Korea-origin botulinum toxin manufacturing becoming part of the global aesthetic-toxin market. Alongside Daewoong Pharmaceutical and Medytox, it shows how Korean companies now shape product availability, export naming, regulatory filings, and comparison conversations beyond Korea.
The toxin business is one part of Hugel’s broader aesthetics portfolio, which also includes hyaluronic acid fillers, skin boosters, sutures, and cosmetics. (Hugel company overview 🔗)
Hugel adds another major type A product family to a market often framed around older Western brands. That does not mean Letybo or Botulax is unit-equivalent, clinically interchangeable, longer-lasting, safer, or superior to another botulinum toxin product.
Regulatory and market interpretation
Section titled “Regulatory and market interpretation”Letybo’s U.S. approval gives Hugel a concrete U.S. label anchor, but the approved use is narrow: temporary improvement of moderate to severe glabellar lines in adults. Other treatment contexts, regions, or names require separate local product information rather than assumptions based on the broader Hugel portfolio.
Hugel’s international footprint also illustrates why product-name interpretation matters. Botulax, Letybo, Aestox, Hugeltox, and other names may appear in related commercial discussions, but readers should distinguish company identity, product identity, local approval, and prescribing label before making comparisons.
Comparison limits
Section titled “Comparison limits”- Botulax and Letybo should not be treated as automatically identical across all regulatory markets.
- Letybo units are not interchangeable with units of Botox, Dysport, Xeomin, Jeuveau, Daxxify, or other botulinum toxin products.
- A manufacturing-quality statement does not by itself establish product approval in a specific country.
- Export names and regional names are market identifiers, not evidence of clinical equivalence.
- U.S. Letybo interpretation should stay tied to the current FDA-approved prescribing information.

